Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03548961 | Organ Preservation in Early Rectal Cancer Patients | active not recruiting | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04503694 | Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer(REGINA) | active not recruiting | Phase 2 | 72 | Jules Bordet InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06890624 | mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer(OPTICAL-3) | not yet recruiting | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT06903858 | Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer(PICC-3) | recruiting | Phase 2 | 105 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07604909 | A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06959550 | Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer | recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07587619 | Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion | active not recruiting | Phase 1 / Phase 2 | 52 | University of Southern CaliforniaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07359456 | Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases(COLIBRI-GI) | not yet recruiting | Phase 2 | 130 | UNICANCEROTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07594925 | Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03386500 | Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT06824064 | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer(VISTA-1) | recruiting | Phase 2 | 150 | Riboscience, LLC.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT07581626 | Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06300463 | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | recruiting | Phase 2 | 24 | Weill Medical College of Cornell UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06580574 | Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers | recruiting | Phase 2 | 34 | Peking UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07586813 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors(N01-A-PICIT-GI) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07365592 | Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC(Neo-CD) | recruiting | Phase 1 / Phase 2 | 138 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07585279 | A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 408 | Hebei Medical University Fourth HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05672524 | A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | recruiting | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07446387 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 70 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581912 | Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases(FALCO) | recruiting | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06758830 | Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. | recruiting | Phase 2 / Phase 3 | 400 | National Cancer Center Affiliate of Vilnius University Hospital Santaros KlinikosOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05694936 | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 38 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 8, 2026 | clinicaltrials |
| NCT07448142 | Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | recruiting | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07570914 | Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | not yet recruiting | Phase 2 | 28 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 6, 2026 | clinicaltrials |
| NCT05692024 | COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER(COMMENCER) | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 165 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07503756 | JS212 Combination Therapies in Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05961709 | The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07283367 | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | recruiting | Phase 1 / Phase 2 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561060 | Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy(TNTIT) | recruiting | Phase 1 / Phase 2 | 50 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562490 | A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer(CLEAR-04) | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562503 | Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer(CLEAR-03) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562659 | Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer(CLEAR-01) | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562711 | Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer(CLEAR-02) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05776381 | The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp | not yet recruiting | Phase 2 | 110 | Vejle HospitalOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07559760 | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07555678 | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer:Chase(Chase) | recruiting | Phase 2 | 241 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06356584 | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases | recruiting | Phase 2 | 62 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06589830 | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Suzhou Teligene Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07381309 | Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM(VVSHIP) | not yet recruiting | Phase 2 | 114 | Jun HuangOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06002789 | Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC | recruiting | Phase 2 | 17 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06204094 | Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer(CASINOs) | recruiting | Phase 2 | 37 | Jinhua Central HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07542262 | Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers(NIVO402025) | enrolling by invitation | Phase 2 | 128 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07549906 | Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study | not yet recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 0 | Apr 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 22, 2026source: clinicaltrials